Skip to main content

Talk Bio

Search This Blog

Novartis to Acquire UK Biotech Myricx Bio for Up to $1.5 Billion to Expand ADC Oncology Pipeline

on July 06, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Novartis has agreed to acquire UK-based Myricx Bio for up to $1.5 billion, including $1.1 billion paid upfront in cash, with up to $400 million in potential milestone payments.

Myricx Bio is a London-headquartered biotech company focused on developing a novel class of antibody-drug conjugate (ADC) payloads based on N-myristoyltransferase inhibitors (NMTi) for treating cancer.

The deal is expected to close in the second half of 2026, subject to customary closing conditions and regulatory approvals.

The acquisition strengthens Novartis’s oncology pipeline by bringing an innovative ADC payload platform in-house, enabling the development of next-generation ADCs for solid tumors and other cancers.

Sources:

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis

News - Myricx Bio

Novartis snaps up UK ADC developer Myricx Bio - pharmaphorum

NGSX News 6th July 2026 - by Albert - Rhymes with Haystack

Novartis übernimmt Myricx Bio für 1,1 Mrd. US-Dollar

Myricx Bio – Developing the first class of ADCs based on NMT ...

Novartis to Buy Myricx Bio for Up to $1.5 Billion

Novartis' Post - LinkedIn

News | Latest Breaking News Stories & Headlines | RTÉ

Myricx Bio Announces £90m ($114m) Series A Financing to ...

Novo Holdings co-leads GBP90 million Series a financing for Myricx Bio to advance a novel payload class for antibody-drug conjugates

Novartis strikes deal with UK biotech for up to US$1.7 billion

Novartis Strikes $1.7 Billion Drug Target Deal With UK Biotech

Novartis Pays China’s Baiyu $70M Upfront, with $1.1B in Potential Milestones for Small Molecule Cancer Candidate

acquisition Antibody-Drug Conjugates Myricx Bio Neoplasms NMTi Novartis therapeutic autologous dendritic cells upfront

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Powered by Blogger

X-Data LLC